Cancer-Killing virus trial launches for patients out of options
NCT ID NCT06910657
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments. Participants receive a single intravenous dose, and researchers will monitor safety, side effects, and any signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IDOV-Immune (a genetically engineered virus that targets and kills cancer cells)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 78 participants, so it is not yet known if the treatment is safe or effective. There is a risk of side effects from the virus, and the therapy may not shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal North Shore Hospital
NOT_YET_RECRUITINGSaint Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
South Texas Accelerated Research Therapeutics
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••